Background. The goal of this study was to develop a validated prediction rule for identification of patients harboring vancomycin-resistant enterococci (VRE) at hospital admission. Methods. A model for the prediction of patients harboring VRE at admission was created and validated by assigning weighted point values to independent risk factors associated with harboring VRE at admission, in 2 different cohorts of patients from 2 tertiary care hospitals in Boston, Massachusetts. Patients with VRE isolated from clinical culture samples collected within 48 h of hospital admission were compared with patients not harboring VRE. To assess the diagnostic accuracy of the prediction rule, the main outcome measures were patient demographic characteristics, comorbid illnesses, hospitalizations, and antibiotic exposure.
Widespread acquisition of vancomycin-resistant enterococci (VRE) is associated with grave implications in health care, including high morbidity and mortality rates and excess health care costs [1] . The recent recovery of strains of vancomycin-resistant Staphylococcus aureus (VRSA), which were produced by the transfer of vancomycin-resistant genes from VRE to S. aureus isolates [2, 3] , further emphasizes the urgent need to prevent de novo acquisition of VRE.
VRE have become endemic in numerous health care institutions [4] [5] [6] [7] . This endemic state is achieved by a constant influx of VRE into the health care setting, from newly admitted patients who are colonized or infected with VRE, followed by cross-transmission between hospitalized patients with de novo VRE acquisition and an efflux of VRE from the health care setting, owing to patient discharge or death. Developing effective prevention strategies necessitates an understanding of the various components required to achieve this endemic state.
The majority of prevention strategies focus on the middle component-that is, the prevention of crosstransmission between hospitalized patients. However, the influx of VRE into the health care setting may be an even more important factor in establishing endemicity, because eradication of VRE from a health care institution could be achieved, in theory, by prevention of this influx [8] . A mathematical model describing the transmission dynamics of VRE in an outpatient hemodialysis unit validates this concept. This model demonstrates that, although 100% compliance with hand washing or a nurse-to-patient ratio of 1:1 would substantially decrease the overall prevalence of VRE in the outpatient hemodialysis unit, prevention of the influx of VRE into the unit is the only intervention that completely eradicates VRE from this patient population over time [8] .
Impeding the influx of VRE into a health care institution would require a program of active surveillance of culture samples obtained to detect gastrointestinal VRE colonization among all patients admitted to a hospital. Contact isolation precautions would be applied to patients with VRE colonization, to prevent cross-transmission of VRE to other hospitalized patients [9] . Given the low prevalence of VRE at admission, the screening of all newly admitted patients would not be feasible. A more efficient strategy would be to perform targeted screening of patients at high risk of harboring VRE at admission. This strategy would greatly reduce the number of negative culture results during screening and, ultimately, would both decrease the burden on hospital personnel and limit health care costs.
To identify the characteristics of patients at high risk for having VRE colonization at hospital admission, a 2-medical center, 6-year epidemiological analysis of patients harboring VRE was performed. From this analysis, a clinical prediction rule was developed that could identify patients at high risk for having VRE colonization at admission and that could indicate which subgroup of newly admitted patients required screening for VRE and contact isolation. The prediction rule then was validated by analysis of data from a separate cohort of highrisk patients, by means of standard methodological criteria [10] .
PATIENTS AND METHODS
Derivation set. The derivation study was performed at the Beth Israel Deaconess Medical Center, Boston, and was approved by the hospital's Institutional Review Board. This hospital is a 430-bed tertiary care teaching hospital with 6 intensive care units (ICUs) and an average of 26,000 patient admissions per year.
Patient selection. From July 1997 through December 2001, clinical culture samples yielding enterococci were identified through a review of the computer summary report of the microbiology laboratory. Patients were enrolled only once, at the first recovery of VRE within 48 h of hospital admission during the study period. To avoid bias in identification of patients at high risk of harboring VRE, patients in whom VRE was detected by screening of rectal swab samples were excluded from the analysis.
To identify the risk factors for isolation of VRE from clinical culture samples obtained within 48 h of hospital admission, a case-control study was performed. A case patient was defined as an adult patient (age, у18 years) from whom VRE was isolated from at least 1 clinical culture sample collected within 48 h of hospital admission. One control subject was selected for each case patient. Control subjects were chosen from among all adult patients admitted to the hospital during the same year and from whom enterococci were not isolated during their hospital stay. If 11 control subject was available per case patient, the control subject who was admitted to the hospital at the date and time closest to those of the case patient was chosen.
Data collection. Electronic medical records for inpatient admissions and outpatient medical visits, including visits to physicians' offices and home visits from nurses, and databases of microbiology results and pharmacy records were reviewed. Data collected at study enrollment included patient demographic characteristics, whether the patient had been transferred from another hospital or was a resident of a long-term care facility or nursing home, previous hospitalization within 1 year of enrollment, ambulatory status, whether the patient was receiving long-term hemodialysis, and surgical procedures undergone during the 30 days prior to study enrollment. A composite score for comorbid illnesses was derived by using the Charlson score [11] . Antibiotics administered for at least 48 h during a 30-day period prior to study enrollment were recorded. Information on inpatient antibiotic exposure during previous hospitalizations was obtained through a computerized pharmacy database. Information on outpatient antibiotic exposure was determined from this database and from records of outpatient and nursing home visits. For the risk-factor analysis, exposure to oral and intravenous antibiotics was analyzed by antibiotic and by class and included penicillins, vancomycin, cephalosporins, antibiotics with predominantly anaerobic activity (metronidazole and clindamycin), aminoglycosides, quinolones, and imipenem. With regard to the prediction rule, antibiotics were analyzed as a group, and the mean number of different antibiotics received in the previous 30 days was used to dichotomize the data. Records of microbiology results also were reviewed for recovery of VRE or methicillin-resistant S. aureus (MRSA) in the 12 months prior to enrollment.
Validation set. The validation study was performed at the Brigham and Women's Hospital, Boston, and was approved by the hospital's Institutional Review Board. This hospital is a 750-bed tertiary care center with 8 ICUs, with 10 beds each, and ∼40,000 patient admissions per year. Criteria for patient inclusion and definitions for case patients and control subjects that were identical to those used for the derivation set were applied to the validation cohort, with the following 2 exceptions. First, Microbiological analysis. Enterococci were identified by use of standard methods, including analysis of colony morphology, Gram stain, and standard biochemical tests [12] . APIRapid Strep Strips (bioMérieux Vitex) were used to identify species. Screening for vancomycin resistance was performed by plating of isolates on brain-heart infusion media agar (Becton Dickinson) with 6 mg/mL vancomycin, and resistance was confirmed by MIC testing using the broth microdilution method [13] . Isolates with an MIC of vancomycin of у32 mg/mL were classified as resistant.
Statistical analysis. Quantitative variables were tested for distribution and were compared by using the Kruskal-Wallis test. Differences in group proportions were assessed by using the x 2 test. Age was made dichotomous at the mean value. Potential risk factors for harboring VRE were analyzed by univariate analysis. Variables with an a value !0.05 were included in the regression analysis, and backward stepwise variable selections were performed, to define the best-fitting model. The discriminant ability of the models with regard to the derivation, validation, and combined cohorts was assessed by means of the area under the receiver operating characteristic (ROC) curve [14] . To develop the prediction rule, a scoring system using point values was developed. The natural logarithm of the OR for each risk factor selected by the logistic regression model was multiplied by 2 and rounded to the nearest integer. Sensitivity and specificity, with 95% CIs, for the prediction rule at different cut-off values, the positive predictive value (PPV), and the negative predictive value (NPV) were obtained by using standard definitions and methods [15, 16] . Statistical analysis was performed by using Intercooled Stata software, version 7.0 (Stata Statistical Software). Accuracy of the prediction rule in identification of patients harboring VRE at hospital admission. A summary of the diagnostic accuracy of the risk index score, stratified by different Figure 2 displays the ROC curves for the derivation, validation, and combined cohorts, for different scores. Extrapolated PPVs and NPVs for different prevalences of VRE recovery at hospital admission are shown in figure 3 . Because this risk index score would be targeted for patients at high risk of harboring VRE, defined as those patients with a score of у10, the prevalence of this subgroup of patients was estimated by using data from the combined cohort, as follows. We assumed that 2% of patients admitted to an institution will have a score of у10. This percentage was derived from the number of control subjects with a score of у10. Case patients with a score of у10 were excluded, because their contribution to the percentage of patients with a score of у10 was minimal. Thus, of the 66,000 patients admitted per year to both hospitals, 1320 (2%) would have a score у10. During the last 12 months of patient enrollment for the derivation and validation cohorts, 27 and 23 patients, respectively, were found to harbor VRE at hospital admission. Of these 50 patients, we estimated that 22 patients (44% of VRE-positive patients correctly identified by the score) would have a score of у10. If the use of clinical culture samples identifies only 1 of 10 patients with VRE colonization [6] , then ∼220 patients would have VRE colonization at hospital admission. Thus, the prevalence of VRE among patients with a score of у10 is assumed to be 17% (220 of 1320 patients). At this prevalence, the PPV and NPV of a risk score of у10 are 81% and 89.5%, respectively (figure 3). 
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Limiting the dissemination of VRE throughout a health care institution requires a comprehensive approach that targets the various components required to sustain VRE endemicity. These components include the influx of VRE into the institution from patients harboring VRE at hospital admission, dissemination of VRE from these patients by de novo acquisition by other hospitalized patients, and an efflux of VRE out of the institution. This 2-medical center study addresses the importance of the influx of VRE into the health care institution, an essential step in the propagation of VRE and the establishment of endemicity. In this study, a significant increase in the number of patients with VRE infection or colonization at hospital admission, from 0.56 patients per 1000 admissions in 1998 to 1.5 patients per 1000 admissions in 2001, was documented. The 3-fold increase over a 4-year period suggests a troubling trend for the future and emphasizes the need for early identification of these patients by means of prompt implementation of measures to limit the at-risk time for the spread of VRE from these patients.
The clinical prediction rule developed and validated in this 2-medical center study provides a very specific test that identifies patients with VRE infection or colonization at hospital admission, among a high-risk group of patients. Six variables were identified, for which data are easily obtained during assessment of patients, and weighted scores were applied: the variables were age of 160 years, hospitalization in the previous year, exposure to у2 antibiotics within the previous 30 days, transfer from another hospital or long-term care facility, requirement for long-term hemodialysis, and history of MRSA infection. When a cut-off value of у10 was used for the point score, the specificity of this prediction rule was 98% for the combined derivation and validation cohorts. When the prevalence of VRE colonization was assumed to be 17% among patients with a score у10 at hospital admission, the PPV and NPV for the prediction rule were 81% and 90%, respectively. The predictive values were similar for both cohorts of study patients, who were from 2 different hospitals, further validating the accuracy of the prediction rule. These results suggest that use of this prediction rule for patients who have a score of у10 Figure 2 . Receiver operating characteristic (ROC) curves displaying sensitivity versus specificity for scoring system comparing patients with and those without vancomycin-resistant enterococci colonization at hospital admission, for the derivation cohort (dotted line), the validation cohort (dashed line), and the combined cohort (solid line). The area under the ROC curve is 87% for the derivation cohort, 96% for the validation cohort, and 92% for the combined cohort. at hospital admission would correctly identify a large proportion of patients harboring VRE at hospital admission.
Screening programs for identification of VRE colonization among patients already hospitalized have been studied extensively [17] [18] [19] [20] [21] [22] . These programs are based on the important premise that, for every patient from whom VRE is recovered from clinical culture samples, many other patients with VRE colonization have not been identified [6, 23, 24] . Tremendous benefits from these programs have been achieved by decreasing over time the overall prevalence of VRE and the number of VRE infections [18, 20] . The cost-effectiveness of this approach also has been demonstrated [18, 25, 26] . These strategies target the middle component of the endemic state-that is, cross-transmission among hospitalized patients. The clinical prediction rule in this study provides an additional strategy by targeting the influx of VRE into the hospital setting and identifying patients harboring VRE at hospital admission. This strategy would limit the potential for VRE dissemination from these patients with unrecognized reservoirs at the start of their hospitalization, as opposed to the strategies mentioned above, which use screening programs to target patients already hospitalized. Although the influx of VRE into the hospital would not change, the benefit of early detection is obvious, because the time period in which VRE dissemination could occur would be greatly reduced. By limiting the implementation of this clinical prediction rule to only those patients with a point score of у10 at hospital admission, the number of patients requiring screening would be greatly reduced, increasing the feasibility of this strategy. The minimal cost and inconvenience associated with obtaining and processing a rectal swab sample also facilitates the successful implementation of this screening program [18] .
Implementation of this prediction rule in the clinical setting would require 2 steps. First, patients with a point score of у10 at hospital admission would be identified as at high risk of harboring VRE. Second, VRE infection-control precautions would be applied, on an empirical basis, to this group of patients until results of the screening rectal culture were available. Alternatively, screening could be done and precautions applied only after VRE were detected in the rectal swab sample. The latter approach would be favored only in those circumstances in which resources are limited. Moreover, many hospitals have mechanisms that track patients harboring VRE and automatically apply precautions at readmission. For these hospitals, the application of this clinical prediction rule will provide an additional benefit by identifying patients not known to have harbored VRE.
There were several limitations in this study that require discussion. First, although a cohort study design in which surveillance rectal culture samples for VRE detection were obtained from every patient at admission to the hospital would have been preferable, the number of patients harboring VRE at hospital admission necessitated a case-control study design, which is optimal for infrequent positive outcomes. Second, although a cost-effective analysis demonstrating the beneficial impact of implementing this clinical prediction rule for the screening of high-risk patients at hospital admission was not performed, numerous cost-effective analyses of VRE-screening programs for hospitalized patients have been performed and have shown substantial cost reductions [18, 25, 26] . For MRSA detection, the screening of high-risk patients at hospital admission, with implementation of contact precautions, is the most cost-effective strategy [27] . Third, although the overall number of patients harboring VRE at hospital admission was low, only clinical culture samples were used to detect potential case patients. If patients had been screened for VRE colonization by culture of rectal swab samples, the prevalence would have been substantially higher [6, 14, 23, 24] . Furthermore, the marked increase in the number of patients harboring VRE at hospital admission during the years of the study emphasizes the need to focus on this reservoir of VRE. Last, the PPV of this clinical prediction rule decreases substantially at rates of VRE prevalence of !10% among patients with a score of у10 at hospital admission. Thus, implementation of this clinical prediction rule may be more effective in hospitals with 110% of patients with a point score of у10 and with VRE colonization at hospital admission.
Despite ongoing efforts to limit the increase in the number of patients who harbor VRE, rates of VRE colonization continue to increase throughout the world. The clinical prediction rule developed and validated in this 2-center study provides a novel and diagnostically accurate strategy for the potential prevention of VRE dissemination from the reservoir of VRE entering the hospital and, ultimately, for a decrease in crosstransmission and de novo acquisition of VRE. The minimal cost, inconvenience, and discomfort and the proven reduction in cross-transmission of VRE with the use of screening programs lend further evidence that this strategy could have a substantial impact on the continual increase of VRE colonization and infection.
